Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK known ✓ | Q9UM73 | 3/20 | 0.54 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.50 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 3/20 | 0.50 |
| ▸ | HTR3B known ✓ | O95264 | 3/20 | 0.50 |
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.50 |
| ▸ | HTR3D known ✓ | Q70Z44 | 3/20 | 0.50 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 3/20 | 0.50 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.50 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.50 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.50 |
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.49 |
| ▸ | HTR1D known ✓ | P28221 | 2/20 | 0.49 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.49 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.49 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7556184 | 0.99 | ALK (0.55) | ALKMAPTTHRBADRB1HTR3E | |
| SCHEMBL22601531 | 0.85 | ADRB1 (0.53) | ALKMAPTADRB1HTR3EHTR3B | |
| SCHEMBL27945631 | 0.84 | ALDH1A1 (0.50) | MAPTALDH1A1HTR2CLMNA | |
| SCHEMBL14922743 | 0.83 | CHRNB2 (0.48) | ALKMAPTTHRBADRB1HTR3E | |
| Hydrochloric Acid SCHEMBL7711565 | 0.82 | ADRB1 (0.59) | MAPTADRB1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL2156292 | 0.82 | ADRB1 (0.59) | MAPTADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL11177028 | 0.80 | HTR3E (0.58) | MAPTTHRBADRB1HTR3EHTR3B | |
| SCHEMBL361649 | 0.80 | ADRB1 (0.61) | MAPTADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL2766132 | 0.79 | ADRB1 (0.56) | MAPTADRB1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL2276790 | 0.79 | THRB (0.56) | MAPTTHRBADRB1HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368204-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | Salix Pharmaceuticals, Ltd | 2015-12-24 | — | — | US | disclosed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20150011564-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | SPROUT PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8722682-B2 | Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity | SPROUT PHARMACEUTICALS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2097389-B1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INT (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20110015207-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2097389-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | Boehringer Ingelheim International GmbH (DE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008074795-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-26 | — | — | WO | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | ALK 1161/4885ADRB1 1885/4885HTR3E 1008/4885 |
| US-20150011564-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | HTR3B, HTR3A, HTR1E | ALK 1905/4885ADRB1 158/4885HTR3E 6/4885 |
| US-20150368204-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | HTR3B, HTR3A, HTR1E | ALK 2050/4885ADRB1 156/4885HTR3E 7/4885 |
| US-20110015207-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | HTR3A, HTR3B, NPSR1 | ALK 1831/4885ADRB1 101/4885HTR3E 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.